Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Gruia · SciRah

Researcher profile · Semantic Scholar

G. Gruia

Share profile

G. Gruia — researcher profile on SciRah

h-index: 14
Works: 25
Citations: 5,349

Most-cited papers

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
J. Douillard, D. Cunningham, A. Roth, M. Navarro +9 more
2000The Lancet3,306 citations Open access
Semantic Scholar
Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.
S. Giacchetti, M. Itzhaki, G. Gruia, R. Adam +10 more
1999Annals of Oncology662 citations Open access
Semantic Scholar
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
C. M. R. Rocha Lima, M. R. Green, R. Rotche, W. Miller +6 more
2004Journal of Clinical Oncology619 citations
Semantic Scholar
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
L. Saltz, J. Douillard, N. Pirotta, M. Alakl +5 more
2001The Oncologist156 citations Open access
Semantic Scholar
Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer.
J. Misset, V. Diéras, G. Gruia, Hugues Bourgeois +9 more
1999Annals of Oncology132 citations Open access
Semantic Scholar
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study
E. Van Cutsem, L. Dirix, J. Van Laethem, S. Van Belle +8 more
2005British Journal of Cancer119 citations Open access
Semantic Scholar
Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study.
J. V. Van Riel, C. V. van Groeningen, M. Kedde, H. Gall +5 more
2002Clinical Cancer Research69 citations
Semantic Scholar
Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
V. Herben, J. Schellens, M. Swart, G. Gruia +3 more
1999Journal of Clinical Oncology56 citations
Semantic Scholar
A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.
E. Van Cutsem, C. Pozzo, H. Starkhammar, L. Dirix +8 more
1998Annals of Oncology51 citations Open access
Semantic Scholar
Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver.
J. V. Van Riel, C. V. van Groeningen, J. De Grève, G. Gruia +2 more
2004Annals of Oncology46 citations Open access
Semantic Scholar
Phase 1 and Pharmacokinetic Study of Intravenous Irinotecan in Refractory Solid Tumor Patients with Hepatic Dysfunction
L. Schaaf, L. Hammond, S. Tipping, R. Goldberg +13 more
2006Clinical Cancer Research36 citations Open access
Semantic Scholar
A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer
N. E. Schoemaker, I. Kuppens, V. Moiseyenko, B. Glimelius +18 more
2004British Journal of Cancer32 citations Open access
Semantic Scholar
Phase I study of irinotecan and raltitrexed in patients with advanced astrointestinal tract adenocarcinoma
H. Ford, D. Cunningham, P. Ross, S. Rao +6 more
2000British Journal of Cancer27 citations Open access
Semantic Scholar
Phase I dose finding study of irinotecan (CPT-11) over a short i.v. infusion combined with a fixed dose of 5-fluorouracil (5-FU) protracted continuous i.v. infusion in patients with advanced solid tumours
J. Sastre, L. Paz-Ares, E. Díaz-Rubio, H. Cortés-Funés +6 more
199714 citations
Semantic Scholar
A randomized phase II trial assessing irinotecan (IRI) and 5FU/folinic acid (LV), “Mayo regimen”, in first line palliative chemotherapy patients (pts) with metastatic colorectal cancer (MCRC)
C. Pozzo, S. Pyrhönen, I. Bodrogi, J. Szántó +8 more
199912 citations
Semantic Scholar
Phase I and pharmacokInetic (PK) study of Irinotecan (CPT11) with a prolonged (14D) infusion schedule
V. Herben, J. Schellens, M. Swart, G. Gruia +2 more
19975 citations
Semantic Scholar
A case for time to tumor progression (TTP) as the primary (1o) efficacy endpoint in 1st-line metastatic colorectal cancer (MCRC) therapy: Correlation of TTP and overall survival (OS).
L. Miller, G. Elfring, G. Gruia, S. Hirawat +2 more
2004Journal of Clinical Oncology3 citations
Semantic Scholar
FDA drug information that never reaches clinicians.
J. Hohneker, S. Ericson, G. Gruia
2010New England Journal of Medicine2 citations
Semantic Scholar
Irinotecan (Iri) in combination with high-dose infusional (HDI) 5FU/FA either weekly or bi-weekly: evidence of survival advantage and quality of life (QoL) improvement in metastatic colorectal cancer (MCRC)
P. Rougier, D. Cunningham, A. Roth, J. Germá +9 more
19992 citations
Semantic Scholar
Phase I dose finding study of irinotecan hydrochloride trihydrate (CPT11) with tomudex (TX.) in patients with 5-FU refractory colorectal cancer
D. Cunningham, P. Ross, A. Webb, M. Allen +3 more
19972 citations
Semantic Scholar
A case for time to tumor progression (TTP) as the primary (1o) efficacy endpoint in 1st-line metastatic colorectal cancer (MCRC) therapy: Correlation of TTP and overall survival (OS)
L. Miller, G. Elfring, G. Gruia, S. Hirawat +2 more
20041 citations
Semantic Scholar
Treatment with a nonanthracycline regimen in advanced breast cancer: vinorelbine, cyclophosphamide, and 5-fluorouracil with folinic acid.
F. Turpin, A. Lluch, M. Closon, G. Gruia +4 more
1999American Journal of Clinical Oncology1 citations
Semantic Scholar
P-208 A phase II study of J-107088 in previously treated patients with advanced non-small cell lung cancer (NSCLC)
S. Kalmadi, K. Dragnev, T. Lynch, J. Crawford +3 more
20030 citations
Semantic Scholar
374 Vinorelbine, 5 fluorouracil, leucovorin and cyclophosphamide as first line chemotherapy in metastatic breast cancer (MBC)
P. Turpin, A. Lluch, M. Closon, G. Gruia +5 more
19950 citations
Semantic Scholar
935 A phase I study of the combination of docetaxel (D) and adriamicin (AD) in first line CT treatment of metastatic breast cancer (MBC)
V. Diéras, G. Gruia, P. Pouillart, E. Cvitkovic +4 more
19950 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Miller×5
Invite
L. Miller — researcher profile on SciRah
G. Elfring×4
Invite
G. Elfring — researcher profile on SciRah
J. Douillard×3
Invite
J. Douillard — researcher profile on SciRah
A. Roth×3
Invite
A. Roth — researcher profile on SciRah

×3

Invite

M. Alakl — researcher profile on SciRah

Invite

L. Saltz — researcher profile on SciRah

Invite

D. Sibaud — researcher profile on SciRah

W. W. ten Bokkel Huinink×3

Invite

W. W. ten Bokkel Huinink — researcher profile on SciRah

D. Cunningham×3

Invite

D. Cunningham — researcher profile on SciRah

Invite

R. James — researcher profile on SciRah

Invite

P. Karásek — researcher profile on SciRah

Invite

P. Jandík — researcher profile on SciRah